

INOVIO PHARMACEUTICALS, INC.

Form 4

March 11, 2016

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Weiner David B.

2. Issuer Name and Ticker or Trading Symbol  
 INOVIO PHARMACEUTICALS,  
 INC. [INO]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
 660 W. GERMANTOWN  
 PIKE, SUITE 100

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 03/09/2016

☒ Director ☐ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)

(Street)

4. If Amendment, Date Original  
 Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting Person

PLYMOUTH MEETING, PA 19462

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)			
			Code	V	Amount	(D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction	5. Number of Derivative	6. Date Exercisable and Expiration Date	7. Title and Amount Underlying Securities
------------------------	---------------	--------------------------------------	-------------------------------	----------------	-------------------------	---	---

# Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security	any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)	(Instr. 3 and 4)				
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Option	\$ 7.02	03/09/2016	A		16,000		03/09/2016 <sup>(1)</sup>	03/09/2026	Common Stock	16,000
Common Stock Option	\$ 7.02	03/09/2016	A		30,000		03/09/2016 <sup>(2)</sup>	03/09/2026	Common Stock	30,000
Restricted Stock Unit	<sup>(3)</sup>	03/09/2016	A		16,000		<sup>(3)</sup>	<sup>(3)</sup>	Common Stock	16,000
Restricted Stock Unit	<sup>(4)</sup>	03/09/2016	A		30,000		<sup>(4)</sup>	<sup>(4)</sup>	Common Stock	30,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Weiner David B. 660 W. GERMANTOWN PIKE SUITE 100 PLYMOUTH MEETING, PA 19462	X			

## Signatures

/s/ David B.  
Weiner

03/11/2016

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The vesting schedule for the 16,000 options is as follows: 4,000 shares vested on March 9, 2016; 4,000 shares will vest on March 9, 2017; 4,000 shares will vest on March 9, 2018; 4,000 shares will vest on March 9, 2019.
- (2) The vesting schedule for the 30,000 options is as follows: 7,500 shares vested on March 9, 2016; 7,500 shares will vest on March 9, 2017; 7,500 shares will vest on March 9, 2018; 7,500 shares will vest on March 9, 2019.
- (3) Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,000 restricted stock units is as follows: 5,334 shares will vest on March 9, 2017; 5,333 shares will vest on March 9, 2018; 5,333 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.
- (4) Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 30,000 restricted stock units is as follows: 10,000 shares will vest on March 9, 2017; 10,000 shares will vest on March 9, 2018; 10,000 shares

## Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 4

will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.